PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
0.15%
Cash & equivalents yoy growth below half of TRAW's 35.85%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
0.15%
Below half of TRAW's 35.85%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.11%
Below half of TRAW's 35.62%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.73%
1.25-1.5x TRAW's -6.67%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.07%
Below half of TRAW's -70.81%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
0.03%
Below half of TRAW's 35.18%. Michael Burry sees a potential red flag for stagnation or capital shortage.
10.13%
Less than half of TRAW's -5.59%. David Dodd sees a more disciplined AP approach or lower volume.
-6.71%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-10.13%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
6.71%
Less than half of TRAW's -6.62%. David Dodd sees fewer expansions in other current obligations.
8.18%
Less than half of TRAW's -6.32%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-95.12%
Above 1.5x TRAW's -15.11%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
6.04%
Less than half of TRAW's -9.32%. David Dodd sees far fewer liability expansions relative to competitor.
4.76%
Less than half of TRAW's 32.28%. David Dodd sees fewer share issuances vs. competitor.
-2.66%
≥ 1.5x TRAW's -0.79%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Less than half of TRAW's -400.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-0.27%
Below half TRAW's 50.53%. Michael Burry sees potential underperformance in building shareholder capital.
0.03%
Below half TRAW's 35.18%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.42%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-0.28%
Less than half of TRAW's -35.85%. David Dodd sees better deleveraging or stronger cash buildup than competitor.